BOLD logo

BOUNDLESS BIO INC

BOLDNASDAQ
🏆 #4370 by market capUS Equity
$508.86▼ $13.03 (−2.56%)
Simulated price
🔔
Track BOLD
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$59M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
44
Weak
No chart data available for BOLD.

Trading Snapshot

Day Range
$506.92 – $517.99
52-Week Range
$0.96 – $3.16
Volume
$4.34B
Avg Volume
$3.57B
Shares Outstanding
22.5M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$11M
Last Q Revenue
$3M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-2.86
Dividend Yield
—
Dilution (1yr)
+31.7%

Why Investors Own BOLD

  • ✓High-growth profile — revenue up +4.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 37% gross margin and 20% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BOLD logo

BOUNDLESS BIO INC

BOLD
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$64M▼ −13.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$47M▼ −25.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
22.4M▲ +31.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$31M▼ −$10M YoY
StockOtter · stockotter.space

About BOUNDLESS BIO INC

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Price Target

ⓘ
Average Target
$507.92
▼ −0.2% Downside
High Target$583.71
Low Target$408.95
Based on 17 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

BOUNDLESS BIO INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift BOLD price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

BOUNDLESS BIO INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.